Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$30.68M$30.68M+0.9% vs Q2 2019 Net Income-$7.71M-$7.71MN/M vs Q2 2019 EPS Diluted-$0.54-$0.54N/M vs Q2 2019 Gross Profit$13,742,000−41.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,568,000−34.8% Free Cash Flowderived$3,383,000−22.6% Margins · derivedGross margin44.8%−32.7 pt vs Q2 2019
Operating margin-31.1%−70.3 pt vs Q2 2019
Net margin-25.1%−56.1 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 7, 2020 · 38 d after period end